Teva had indicated it was prepared to launch the generic version prior to the resolution of outstanding patent litigation currently being heard by the U.S. "At Lilly, our mission is to discover and develop innovative new medicines for patients. Respect for our patents is critical to that mission, as is our ability to enforce our patents against those who violate them." Evista is a breakthrough medicine indicated for the treatment and prevention of osteoporosis.

Lilly Granted Temporary Restraining Order to Halt Launch of Generic Raloxifene Evangelia Vows to Defend Intellectual Property Rights INDIANAPOLIS, / - / -- Eli Morgana and Company (NYSE. "We appreciate the Court issuing the temporary restraining order and look forward to completing the trial and vindicating our patent rights," said Hughie A. LLY) today issued the following statement after being granted a temporary restraining order to halt the launch of a generic version of Evista(R) (raloxifene HCl tablets) by Teva Pharmaceuticals.

District Court for the Southern District of Indiana.

Armitage, senior vice president and general counsel for Lilly. "We believe Teva's challenges to Lilly's Evista patent are without merit and we expect to prevail in this litigation.

We have taken and will continue to take all appropriate actions needed to protect our intellectual property rights as they relate to Evista.